Business Context and Reporting Period
Corbus Pharmaceuticals Holdings, Inc., an emerging growth company, filed this Form 8-K on January 29, 2019. The report addresses the termination of a material definitive agreement regarding equity financing.
Key Financial Metrics
This filing does not report standard financial performance metrics such as revenue, profit, cash flow, or margins. The only financial data provided relates to the terminated equity offering:
- Total Offering Capacity: Up to $50 million.
- Shares Sold Under Agreement: 1,500,000 shares of Common Stock.
- Aggregate Gross Proceeds: Approximately $11.7 million.
Material Changes
The Company provided notice on January 29, 2019, to terminate the Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co., originally dated January 5, 2018. The termination will become effective on February 8, 2019. The Company stated it does not intend to conduct any further sales under this agreement prior to its termination.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the cessation of this specific sales mechanism. The primary contingency noted is the effective date of the termination (February 8, 2019).
Investor Verification Checklist
- Confirm the effective date of the Sales Agreement termination is February 8, 2019.
- Verify that no further sales were executed under the agreement after the January 29, 2019 notice.
- Review the Company's current cash position and alternative financing plans given the cessation of this $50 million sales facility.
- Check for subsequent filings regarding new financing arrangements or capital raises.